16340083|t|Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.
16340083|a|Reduced glucose utilization and energy metabolism occur early in the course of Alzheimer's disease (AD) and correlate with impaired cognition. Glucose utilization and energy metabolism are regulated by insulin and insulin-like growth factor I (IGF-I), and correspondingly, studies have shown that cognitive impairment may be improved by glucose or insulin administration. Recently, we demonstrated significantly reduced levels of insulin and IGF-I polypeptide genes and their corresponding receptors in advanced AD relative to aged control brains. The abnormalities in gene expression were accompanied by impaired survival signaling downstream through PI3 kinase-Akt. The present work characterizes the abnormalities in insulin and IGF gene expression and receptor binding in brains with different Braak stage severities of AD. Realtime quantitative RT-PCR analysis of frontal lobe tissue demonstrated that increasing AD Braak Stage was associated with progressively reduced levels of mRNA corresponding to insulin, IGF-I, and IGF-II polypeptides and their receptors, tau, which is regulated by insulin and IGF-I, and the Hu D neuronal RNA binding protein. In contrast, progressively increased levels of amyloid beta protein precursor (AbetaPP), glial fibrillary acidic protein, and the IBA1/AIF1 microglial mRNA transcripts were detected with increasing AD Braak Stage. Impairments in growth factor and growth factor receptor expression and function were associated with increasing AD Braak stage dependent reductions in insulin, IGF-I, and IGF-II receptor binding, ATP levels, and choline acetyltransferase (ChAT) expression. Further studies demonstrated that: 1) ChAT expression increases with insulin or IGF-I stimulation; 2) ChAT is expressed in insulin and IGF-I receptor-positive cortical neurons; and 3) ChAT co-localization in insulin or IGF-I receptor-positive neurons is reduced in AD. Together, these data provide further evidence that AD represents a neuro-endocrine disorder that resembles a unique form of diabetes mellitus (? Type 3) and progresses with severity of neurodegeneration.
16340083	0	7	Insulin	Gene	3630
16340083	95	114	Alzheimer's disease	Disease	MESH:D000544
16340083	144	157	acetylcholine	Chemical	MESH:D000109
16340083	167	174	glucose	Chemical	MESH:D005947
16340083	238	257	Alzheimer's disease	Disease	MESH:D000544
16340083	259	261	AD	Disease	MESH:D000544
16340083	282	300	impaired cognition	Disease	MESH:D003072
16340083	302	309	Glucose	Chemical	MESH:D005947
16340083	361	368	insulin	Gene	3630
16340083	373	401	insulin-like growth factor I	Gene	3479
16340083	403	408	IGF-I	Gene	3479
16340083	456	476	cognitive impairment	Disease	MESH:D003072
16340083	496	503	glucose	Chemical	MESH:D005947
16340083	507	514	insulin	Gene	3630
16340083	589	596	insulin	Gene	3630
16340083	601	606	IGF-I	Gene	3479
16340083	671	673	AD	Disease	MESH:D000544
16340083	811	821	PI3 kinase	Gene	5295
16340083	822	825	Akt	Gene	207
16340083	879	886	insulin	Gene	3630
16340083	983	985	AD	Disease	MESH:D000544
16340083	1077	1079	AD	Disease	MESH:D000544
16340083	1166	1173	insulin	Gene	3630
16340083	1175	1180	IGF-I	Gene	3479
16340083	1186	1192	IGF-II	Gene	3481
16340083	1227	1230	tau	Gene	4137
16340083	1254	1261	insulin	Gene	3630
16340083	1266	1271	IGF-I	Gene	3479
16340083	1395	1402	AbetaPP	Gene	351
16340083	1405	1436	glial fibrillary acidic protein	Gene	2670
16340083	1446	1450	IBA1	Gene	199
16340083	1451	1455	AIF1	Gene	199
16340083	1514	1516	AD	Disease	MESH:D000544
16340083	1642	1644	AD	Disease	MESH:D000544
16340083	1681	1688	insulin	Gene	3630
16340083	1690	1695	IGF-I	Gene	3479
16340083	1701	1716	IGF-II receptor	Gene	3482
16340083	1726	1729	ATP	Chemical	MESH:D000255
16340083	1742	1767	choline acetyltransferase	Gene	1103
16340083	1769	1773	ChAT	Gene	1103
16340083	1825	1829	ChAT	Gene	1103
16340083	1856	1863	insulin	Gene	3630
16340083	1867	1872	IGF-I	Gene	3479
16340083	1889	1893	ChAT	Gene	1103
16340083	1910	1917	insulin	Gene	3630
16340083	1922	1936	IGF-I receptor	Gene	3480
16340083	1971	1975	ChAT	Gene	1103
16340083	1995	2002	insulin	Gene	3630
16340083	2006	2020	IGF-I receptor	Gene	3480
16340083	2052	2054	AD	Disease	MESH:D000544
16340083	2107	2109	AD	Disease	MESH:D000544
16340083	2123	2147	neuro-endocrine disorder	Disease	MESH:D004700
16340083	2180	2197	diabetes mellitus	Disease	MESH:D003920
16340083	2241	2258	neurodegeneration	Disease	MESH:D019636
16340083	Association	MESH:D005947	3479
16340083	Association	3630	4137
16340083	Association	MESH:D005947	3630
16340083	Association	1103	3480
16340083	Negative_Correlation	MESH:D000544	1103
16340083	Association	MESH:D000109	MESH:D000544
16340083	Association	MESH:D000544	2670
16340083	Association	MESH:D000544	3482
16340083	Negative_Correlation	MESH:D000544	3479
16340083	Positive_Correlation	MESH:D000544	199
16340083	Positive_Correlation	1103	3630
16340083	Positive_Correlation	MESH:D000544	351
16340083	Negative_Correlation	MESH:D005947	MESH:D000544
16340083	Negative_Correlation	MESH:D000544	3481
16340083	Association	MESH:D000544	3630
16340083	Positive_Correlation	3479	4137
16340083	Negative_Correlation	MESH:D000255	MESH:D000544
16340083	Association	MESH:D005947	MESH:D003072
16340083	Positive_Correlation	1103	3479
16340083	Association	MESH:D000109	3630
16340083	Negative_Correlation	MESH:D003072	3630
16340083	Association	MESH:D000544	4137

